Calliditas Therapeutics Ab Stock Performance
| CLTEF Stock | USD 0.70 0.15 27.27% |
Calliditas Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 95.0, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Calliditas Therapeutics will likely underperform. Use Calliditas Therapeutics downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to analyze future returns on Calliditas Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Calliditas Therapeutics AB are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Calliditas Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 996.3 M | |
| Total Cashflows From Investing Activities | -24.3 M |
Calliditas |
Calliditas Therapeutics Relative Risk vs. Return Landscape
If you would invest 89.00 in Calliditas Therapeutics AB on September 30, 2025 and sell it today you would lose (19.00) from holding Calliditas Therapeutics AB or give up 21.35% of portfolio value over 90 days. Calliditas Therapeutics AB is currently producing 27.86% returns and takes up 178.5096% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Calliditas, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Calliditas Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calliditas Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Calliditas Therapeutics AB, and traders can use it to determine the average amount a Calliditas Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1561
| Best Portfolio | Best Equity | CLTEF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Calliditas Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Calliditas Therapeutics by adding it to a well-diversified portfolio.
Calliditas Therapeutics Fundamentals Growth
Calliditas Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Calliditas Therapeutics, and Calliditas Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Calliditas Pink Sheet performance.
| Return On Equity | -0.62 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (1.55) % | |||
| Current Valuation | 496.05 M | |||
| Shares Outstanding | 59.58 M | |||
| Price To Book | 5.22 X | |||
| Price To Sales | 14.67 X | |||
| Revenue | 229.35 M | |||
| EBITDA | (524.46 M) | |||
| Total Debt | 189.16 M | |||
| Debt To Equity | 0.21 % | |||
| Cash Flow From Operations | (461.59 M) | |||
| Total Asset | 1.46 B | |||
About Calliditas Therapeutics Performance
By analyzing Calliditas Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Calliditas Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Calliditas Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Calliditas Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Calliditas Therapeutics AB , a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. Calliditas Therapeutics is traded on OTC Exchange in the United States.Things to note about Calliditas Therapeutics performance evaluation
Checking the ongoing alerts about Calliditas Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Calliditas Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Calliditas Therapeutics is way too risky over 90 days horizon | |
| Calliditas Therapeutics has some characteristics of a very speculative penny stock | |
| Calliditas Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 229.35 M. Net Loss for the year was (500.29 M) with profit before overhead, payroll, taxes, and interest of 229.35 M. | |
| Calliditas Therapeutics generates negative cash flow from operations | |
| About 14.0% of the company shares are held by company insiders |
- Analyzing Calliditas Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Calliditas Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Calliditas Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Calliditas Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Calliditas Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Calliditas Therapeutics' pink sheet. These opinions can provide insight into Calliditas Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Calliditas Pink Sheet analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |